O
Ovation
Provider of genomic data for the life sciences industry
About Ovation
Ovation.io is a precision medicine startup specializing in the generation and integration of high-value human genomic and multi-omics data, linked with detailed longitudinal clinical information. The company’s platform is designed to accelerate drug discovery and development by providing disease-specific genomic and transcriptomic data cohorts that offer the scale, diversity, and depth necessary for impactful biomarker discovery, target identification, and patient stratification.
For life sciences organizations, Ovation.io delivers comprehensive datasets that support research across various therapeutic areas. Notably, the company has launched specialized datasets, such as a comprehensive research data set of whole genome sequences and longitudinal clinical records for patients treated with GLP-1 agonists, and a multi-omics database for oncology in partnership with ONCare Alliance. Their inflammatory bowel disease (IBD) dataset provides immediate access to diverse patient cohorts, with deep sequencing and curated clinical data spanning the entire patient journey.
For clinical laboratories, Ovation.io offers Ovation LIMS, a laboratory information management system tailored to the needs of molecular diagnostic labs, and the Ovation Research Network, which enables labs to contribute remnant samples for research, thereby supporting the discovery of new treatments.
Ovation.io’s approach emphasizes data quality, diversity, and accessibility, aiming to de-risk and expedite the development of new therapies through robust, clinically relevant datasets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 67.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biotech and Pharma, Techbio, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Dec 2020 | $22M | $86M | SignalFire · David Shaw · Borealis Ventures · Madrona Venture Group | — |
| LATE VC✓Equity / VC | Mar 2019 | $5M | $20M | Borealis Ventures · Zach Weinberg · David Shaw · Madrona Venture Group | — |
Growth signals
Latest recorded traffic for Ovation is 7.7K monthly website visits, up 54% over the last three months. Ovation's team declined 16.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Stage dot O
Series B and later6 investors entered at this stage
- BVBorealis Ventures
Zach Weinberg
David Shaw
Madrona Venture Group
Nat Turner
SignalFire
Other known investors3 additional known investors
Chris Scoggins
Koa Labs
Phil Ferneau
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ovation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ovation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







